| Literature DB >> 29404280 |
Janet Z Liu1, Syed R Ali1, Ethan Bier2, Victor Nizet1,3.
Abstract
Bacillus anthracis, the causative agent of anthrax, has been a focus of study in host-pathogen dynamics since the nineteenth century. While the interaction between anthrax and host macrophages has been extensively modeled, comparatively little is known about the effect of anthrax on the immune function of neutrophils, a key frontline effector of innate immune defense. Here we showed that depletion of neutrophils significantly enhanced mortality in a systemic model of anthrax infection in mice. Ex vivo, we found that freshly isolated human neutrophils can rapidly kill anthrax, with specific inhibitor studies showing that phagocytosis and reactive oxygen species (ROS) generation contribute to this efficient bacterial clearance. Anthrax toxins, comprising lethal toxin (LT) and edema toxin (ET), are known to have major roles in B. anthracis macrophage resistance and systemic toxicity. Employing isogenic wild-type and mutant toxin-deficient B. anthracis strains, we show that despite previous studies that reported inhibition of neutrophil function by purified LT or ET, endogenous production of these toxins by live vegetative B. anthracis failed to alter key neutrophil functions. The lack of alteration in neutrophil function is accompanied by rapid killing of B. anthracis by neutrophils, regardless of the bacteria's expression of anthrax toxins. Lastly, our study demonstrates for the first time that anthrax induced neutrophil extracellular trap (NET) formation.Entities:
Keywords: Bacillus anthracis; anthrax; edema toxin; host-pathogen interactions; innate immunity; lethal toxin; neutrophil extracellular traps; neutrophils
Mesh:
Substances:
Year: 2018 PMID: 29404280 PMCID: PMC5786542 DOI: 10.3389/fcimb.2018.00002
Source DB: PubMed Journal: Front Cell Infect Microbiol ISSN: 2235-2988 Impact factor: 5.293
Figure 1B. anthracis Sterne infection of neutrophil-depleted mice. (A) Mice treated with the neutrophil-depleting 1A8 antibody show increased mortality upon B. anthracis challenge compared to control antibody-treated animals. 1A8 antibody treated, n = 12; Control antibody treated, n = 11. (B) Splenocytes from depleting antibody treated and control antibody treated animals were stained with CD11b and Ly6G antibody, where percentage neutrophil is defined as CD11b+, Ly6G+ cells/all splenocytes, and percentage macrophage/monocytes are defined as CD11b+, Ly6G− cells/all splenocytes. Infected 1A8 antibody treated and infected control antibody treated, n = 18/group; uninfected 1A8 antibody treated and uninfected control antibody treated, n = 6/group. (C) Bacteria recovered from organs (CFU/mg) and blood (CFU/ml) of 1A8 antibody and control antibody treated infected mice. (D) Serum cytokine levels of TNF, IFNγ, and KC from 1A8 antibody treated and control antibody treated mice. *P < 0.05, **P < 0.01, *** P < 0.001.
Figure 2Neutrophil functions during B. anthracis infection. (A) Generation of ROS by neutrophils infected with the indicated strains of B. anthracis. (B) Neutrophil phagocytosis of GFP-expressing B. anthracis strains treated in the presence or absence of cytochalasin D. (C) Representative data of neutrophil migration toward B. anthracis strains through a Transwell system. (D) Densitometry analysis of LL-37 and alpha-defensin dot blots from supernatant of neutrophils infected with the indicated strain of B. anthracis. (E) Neutrophil viability following B. anthracis infection as determined by PI staining. (F) Representative image of SYTOX Green-stained NETs following infected of neutrophils with the indicated B. anthracis strain. (G) Quantification of NET released by neutrophils following B. anthracis infection. Unless otherwise stated, data shown are from a combination of at least three independent experiments.
Figure 3Mechanism of neutrophil anthrax killing. (A) CFU/ml of B. anthracis strains recovered at time 0 and 15 min after neutrophil infection. (B) Neutrophils were pretreated with the indicated compound for 30 min, then infected with wild type B. anthracis Sterne and the percentage of bacterial survival enumerated. Percentage bacterial survival is calculated by dividing the CFU/ml of bacteria recovered in the presence of neutrophils over the CFU/ml of bacteria recovered in the absence of neutrophils. **P < 0.01 and ***P < 0.001. All data shown are from a combination of at least three independent experiments.